Therapeutic advances in the management of gout have renewed interest in the treatment of this common, painful condition. Compliance with European League Against Rheumatism (EULAR) treatment recommendations is poor, with lifestyle advice infrequently offered by doctors or implemented by patients [1]. Inadequate control of hyperuricaemia in gout may lead to chronic tophaceous disease, worsening of joint erosion, absenteeism from work and reduced productivity [2].
展开▼
